Lung Fibrosis Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting lung fibrosis clinical trials across 7 countries. Studies span Not Applicable, Phase 2. Top locations include Amsterdam, North Holland, Netherlands, Bern, Switzerland, Brussels, Belgium. Updated daily from ClinicalTrials.gov.


Lung Fibrosis Trials at a Glance

8 actively recruiting trials for lung fibrosis are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Amsterdam, Bern, and Brussels. Lead sponsors running lung fibrosis studies include Erasme University Hospital, Fondazione IRCCS Policlinico San Matteo di Pavia, and Amsterdam UMC, location VUmc.

Browse lung fibrosis trials by phase

Treatments under study

About Lung Fibrosis Clinical Trials

Looking for clinical trials for Lung Fibrosis? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Fibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

P4O2 ILD Extension

Interstitial Lung DiseasePulmonary FibrosisIPF+7 more
Amsterdam UMC, location VUmc450 enrolled1 locationNCT06644144
Recruiting
Not Applicable

Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease

Lung FibrosisLung Interstitial Disease
Mayo Clinic460 enrolled4 locationsNCT06751069
Recruiting
Not Applicable

Evaluation of the Pulmonary Fibrosis Learning and Self-management Programme (FILIP)

Lung Fibrosis Interstitial
Insel Gruppe AG, University Hospital Bern80 enrolled2 locationsNCT07457463
Recruiting

Impact of Airway Mucus Plugs on Secondary Pulmonary Fibrosis in COPD Patients: A Single-Center Case-Control Study

Lung Fibrosis
Ming Zhong20 enrolled1 locationNCT07236541
Recruiting

Pulmonary Fibrosis Foundation Community Registry

Interstitial Lung DiseasePulmonary FibrosisIdiopathic Pulmonary Fibrosis+1 more
Pulmonary Fibrosis Foundation10,000 enrolled1 locationNCT05382572
Recruiting

PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.

Pulmonary Arterial Hypertension PAHLung Fibrosis Interstitial
Fondazione IRCCS Policlinico San Matteo di Pavia16 enrolled1 locationNCT06917196
Recruiting

Immune Modulation by Exosomes in COVID-19

COVID-19Critical IllnessLung Fibrosis+1 more
University of Ulm40 enrolled1 locationNCT05191381
Recruiting
Phase 2

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

Pulmonary FibrosisIdiopathic Pulmonary FibrosisFAP+1 more
Erasme University Hospital70 enrolled1 locationNCT06189820